Drug interaction profile of TKI alectinib allows effective and
safe treatment of ALK plus lung cancer in the kidney transplant
recipient

J 2021

Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient

BÍLEK, Ondřej, Miloš HOLÁNEK, Jan JUŘICA, Sona STEPANKOVA, Jiri VASINA et. al.

Základní údaje

Originální název

Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient

Autoři

BÍLEK, Ondřej (203 Česká republika, domácí), Miloš HOLÁNEK (203 Česká republika, domácí), Jan JUŘICA (203 Česká republika, domácí), Sona STEPANKOVA (203 Česká republika), Jiri VASINA (203 Česká republika), Iveta SELINGEROVÁ (203 Česká republika, domácí), Alexandr POPRACH (203 Česká republika, domácí), Simona BOŘILOVÁ (703 Slovensko, domácí), Tomáš KAZDA (203 Česká republika, domácí), Igor KISS (203 Česká republika, domácí) a Lenka ZDRAŽILOVÁ DUBSKÁ (203 Česká republika, garant, domácí)

Vydání

International Immunopharmacology, AMSTERDAM, ELSEVIER, 2021, 1567-5769

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.714

Kód RIV

RIV/00216224:14110/21:00124189

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.intimp.2021.108012

UT WoS

000692559700004

Klíčová slova anglicky

ALK plus NSCLC; Kidney transplant; Alectinib; Crizotinib; cyclosporine A; Drug interaction

Štítky

14110516, 14110811, 14110812, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 2. 2022 13:31, Mgr. Tereza Miškechová

Anotace

V originále

ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the interfering co-medication may hamper the anti-cancer therapeutic management. Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with ALK+ lung cancer. Based on therapeutic drug monitoring of cyclosporin A plasma level, the dose of cyclosporine A has been adjusted to achieve a safe and effective therapeutic level in terms of both cancer treatment and kidney transplant condition. Particularly, 15 years upon the kidney transplantation, the stage IV lung cancer patient was treated with the 1st-line chemotherapy, the 2nd-line ALK-TKI crizotinib followed by ALK-TKI alectinib. The successful therapy with ALK-TKIs has been continuing for more than 36 months, including the period when the patient was treated for COVID-19 bilateral pneumonia. Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(Kód CEP: EF16_013/0001826)

Název: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií, PO 1 Posilování kapacit pro kvalitní výzkum

MUNI/A/1249/2020, interní kód MU

Název: Základní výzkum v oblasti farmakokinetiky, neurobiologie závislostí a aplikovaný výzkum v oblasti personalizované farmakoterapie v onkologii (Akronym: SV_Farmakologie2021)

Investor: Masarykova univerzita, Základní výzkum v oblasti farmakokinetiky, neurobiologie závislostí a aplikovaný výzkum v oblasti personalizované farmakoterapie v onkologii

Citovat

BÍLEK, Ondřej, Miloš HOLÁNEK, Jan JUŘICA, Sona STEPANKOVA, Jiri VASINA, Iveta SELINGEROVÁ, Alexandr POPRACH, Simona BOŘILOVÁ, Tomáš KAZDA, Igor KISS a Lenka ZDRAŽILOVÁ DUBSKÁ. Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient. International Immunopharmacology. AMSTERDAM: ELSEVIER, 2021, roč. 99, October 2021, s. 1-6. ISSN 1567-5769. Dostupné z: https://dx.doi.org/10.1016/j.intimp.2021.108012.

@article{1834752,
   author = {Bílek, Ondřej and Holánek, Miloš and Juřica, Jan and Stepankova, Sona and Vasina, Jiri and Selingerová, Iveta and Poprach, Alexandr and Bořilová, Simona and Kazda, Tomáš and Kiss, Igor and Zdražilová Dubská, Lenka},
   article_location = {AMSTERDAM},
   article_number = {October 2021},
   doi = {http://dx.doi.org/10.1016/j.intimp.2021.108012},
   keywords = {ALK plus NSCLC; Kidney transplant; Alectinib; Crizotinib; cyclosporine A; Drug interaction},
   language = {eng},
   issn = {1567-5769},
   journal = {International Immunopharmacology},
   title = {Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient},
   url = {https://www.sciencedirect.com/science/article/pii/S1567576921006482?via%3Dihub},
   volume = {99},
   year = {2021}
}

TY  - JOUR
ID  - 1834752
AU  - Bílek, Ondřej - Holánek, Miloš - Juřica, Jan - Stepankova, Sona - Vasina, Jiri - Selingerová, Iveta - Poprach, Alexandr - Bořilová, Simona - Kazda, Tomáš - Kiss, Igor - Zdražilová Dubská, Lenka
PY  - 2021
TI  - Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient
JF  - International Immunopharmacology
VL  - 99
IS  - October 2021
SP  - 1-6
EP  - 1-6
PB  - ELSEVIER
SN  - 15675769
KW  - ALK plus NSCLC
KW  - Kidney transplant
KW  - Alectinib
KW  - Crizotinib
KW  - cyclosporine A
KW  - Drug interaction
UR  - https://www.sciencedirect.com/science/article/pii/S1567576921006482?via%3Dihub
N2  - ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the interfering co-medication may hamper the anti-cancer therapeutic management. Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with ALK+ lung cancer. Based on therapeutic drug monitoring of cyclosporin A plasma level, the dose of cyclosporine A has been adjusted to achieve a safe and effective therapeutic level in terms of both cancer treatment and kidney transplant condition. Particularly, 15 years upon the kidney transplantation, the stage IV lung cancer patient was treated with the 1st-line chemotherapy, the 2nd-line ALK-TKI crizotinib followed by ALK-TKI alectinib. The successful therapy with ALK-TKIs has been continuing for more than 36 months, including the period when the patient was treated for COVID-19 bilateral pneumonia. Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.
ER  -

BÍLEK, Ondřej, Miloš HOLÁNEK, Jan JUŘICA, Sona STEPANKOVA, Jiri VASINA, Iveta SELINGEROVÁ, Alexandr POPRACH, Simona BOŘILOVÁ, Tomáš KAZDA, Igor KISS a Lenka ZDRAŽILOVÁ DUBSKÁ. Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient. \textit{International Immunopharmacology}. AMSTERDAM: ELSEVIER, 2021, roč.~99, October 2021, s.~1-6. ISSN~1567-5769. Dostupné z: https://dx.doi.org/10.1016/j.intimp.2021.108012.

Podrobný výpis o publikaci